Prognostic factors for survival after surgical palliation of malignant pleural effusion

Journal of Thoracic Oncology

Volumn 5, Issue 10, 2010, Pages 1544-1550

  Pilling, John E ^a   Dusmet, Michael E ^a   Ladas, George ^a   Goldstraw, Peter ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Albumin; Malignant pleural effusion; Mesothelioma; Pleurodesis; Prognosis

Indexed keywords

ALANINE AMINOTRANSFERASE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY MASS; CANCER SURGERY; CANCER SURVIVAL; DISEASE ASSOCIATION; FEMALE; HUMAN; HYPOALBUMINEMIA; HYPOXEMIA; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PALLIATIVE THERAPY; PLEURA BIOPSY; PLEURA EFFUSION; PLEURA MESOTHELIOMA; PLEURODESIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE;

EID: 77958173732     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181e95cb8     Document Type: Article

References (20)

1. Sahn AS. Malignancy metastatic to the pleura. Clin Chest Med 1998; 19:351-361.
2. Petrou M, Kaplan D, Goldstraw P. Management of recurrent pleural effusions: the complementary role of talc pleurodesis and pleuroperitoneal shunting. Cancer 1995;75:801-805.
3. Genc O, Petrou M, Ladas G, et al. The long term morbidity of pleuroperitoneal shunts in the management of recurrent malignant effusions. Eur J Cardiothorac Surg 2000;18:143-146. (Pubitemid 30488809)
4. Cardillo G, Facciolo F, Carbone L, et al. Long term follow up of video-assisted talc pleurodesis in malignant recurrent pleural effusions. Eur J Cardiothorac Surg 2002;21:302-306. (Pubitemid 34134487)
5. Schulze M, Boehle AS, Kurdow R, et al. Effective treatment of malignant pleural effusion by minimal invasive thoracic surgery: thoracoscopic talc pleurodesis and pleuroperitoneal shunts in 101 patients. Ann Thorac Surg 2001;71:1809-1812. (Pubitemid 32554405)
6. Heimburger DC. Malnutrition and nutritional assessment. In: Fauci AS, Braunwald E, Kasper DL, et al. (Eds). Marmon's Principles of Internal Medicine, 17th Edition. New York: McGraw-Hill Medical, 2008: 450-454.
7. Bernard A, Dompsure RB, Hagry O, et al. Early and late mortality after pleurodesis for malignant pleural effusion. Ann Thorac Surg 2002;74: 213-217. (Pubitemid 34734673)
8. Belani CP, Pajeau TS, Bennett CL. Treating malignant pleural effusions cost consciously. Chest 1998;113:78S-85S. (Pubitemid 28051740)
9. Vincent JL, Dubois MJ, Navickis RJ, et al. Hypoalbuminemia in acute illness: is there a rationale for intervention? A meta analysis of cohort studies and controlled trials. Ann Surg 2003;237:319-334.
10. Gibbs J, Cull W, Henderson W, et al. Preoperative serum albumin level as a predictor of operative mortality and morbidity: results from the national VA surgical risk study. Arch Surg 1999;145:36-42. (Pubitemid 29047211)
11. Al-Shabiba R, McMillan D, Angerson W, et al. The relationship between hypoalbuminaemia, tumour volume and the systemic inflammatory response in patients with colorectal liver metastases. Br J Cancer 2004;91:205-207. (Pubitemid 39037059)
12. Forrest L, McMillan D, McArdle C, et al. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small cell lung cancer. Br J Cancer 2003; 89:1028-1030. (Pubitemid 37239206)
13. Pilling JE, Nicholson AG, Harmer C, et al. Prolonged survival due to spontaneous regression and surgical excision of malignant mesothelioma. Ann Thorac Surg 2007;83:314-315. (Pubitemid 44917861)
14. Aelony Y, Yao JF. Prolonged survival after talc poudrage for malignant pleural mesothelioma: case series. Respiration 2005;10:649-655. (Pubitemid 44944463)
15. Edwards J, Abrams KR, Leverment JN, et al. Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax 2000;55:731-735. (Pubitemid 30660898)
16. Aziz T, Jilaihani A, Prakash D. The management of malignant pleural mesothelioma: a single centre experience over ten years. Eur J Cardiothorac Surg 2002;22:298-305. (Pubitemid 34831874)
17. Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status and cell type determine postoperative long term survival in trimodality therapy of malignant pleural mesothelioma: results of 183 patients. J Thorac Cardiovasc Surg 1999;117:54-65.
18. Treasure T, Tan C, Lang-Lazdunski L, et al. The MARS trial: mesothelioma and radical surgery. Interact Cardiovasc Thorac Surg 2006;5:58-59. (Pubitemid 43200170)
19. Burrows CM, Mathews C, Colt HG. Predicting survival in patients with recurrent symptomatic malignant pleural effusions. Chest 2000;117:73-78.
20. Sanchez-Arengol A, Rodriguez-Panadero F. Survival and talc pleurodesis in metastatic pleural carcinoma, revisited: report of 125 cases. Chest 1993;104:1482-1485. (Pubitemid 23327868)